ERBB2 and lung carcinoma: Contrary to the outcome observed for Patient 3, neratinib efficacy has been reported in a ERBB2 I655V transmembrane domain mutation in different lung cancer cell lines52, suggesting the S653C mutation may be functionally different than the I655V mutation.